VANCOUVER, British Columbia, Aug. 9, 2011 /PRNewswire/ — Enox
Biopharma, Inc., a leader in nitric oxide delivery technology for
the prevention of hospital acquired infections today announced on
line publication of scientific results demonstrating superior
efficacy in blocking growth of E.coli on the surface of nitric
oxide releasing devices as compared to current market leader’s
silver coated catheters. The paper was published by Professor
Yossef Av-Gay’s lab at the University of British Columbia.
Enox’s nitric oxide device technology renders medical devices
like catheters and endotracheal tubes antimicrobial by sequestering
nitric oxide within them in a stable state. Nitric Oxide, which is
released by the device over a period of about 2 weeks once used
clinically, is a potent antimicrobial agent without the drug
resistance issues that plague antibiotics. Previous peer reviewed
publications have demonstrated the antimicrobial properties of
catheters treated with our technology in comparison to untreated
catheters.
The paper titled “Comparative efficacy of commercially available
and emerging antimicrobial urinary catheters against E. coli
infection in vitro” was published in the August 2011 issue of the
peer reviewed journal UROLOGY. The paper reports results from an
investigation of the ability of four different types of catheters
to prevent growth of microorganisms suspended in fluid medium
(planktonic growth) and on the surface of catheters in the form of
a biofilm. The study compared a non-antimicrobial catheter, an Enox
nitric oxide releasing catheter, a silver coated catheter and an
antibiotic coated catheter. The study concluded that both the Enox
and antibiotic catheters were effective in preventing planktonic
growth and biofilm formation whereas the silver and uncoated
catheters were not.
“This study confirms the superiority of nitric oxide as an
antimicrobial,” commented Professor Av-Gay, who is the President
and Founder of Enox Bio
‘/>”/>
